|
Model
|
MMP-1
|
MMP-2
|
MMP-3
|
MMP-9
|
MMP-10
|
TIMP-1
|
|---|
|
HR
|
95% CI
|
p value
|
HR
|
95% CI
|
p value
|
HR
|
95% CI
|
p value
|
HR
|
95% CI
|
p value
|
HR
|
95% CI
|
p value
|
HR
|
95% CI
|
p value
|
|---|
|
1
|
1.51
|
1.20; 1.91
|
<0.001
|
1.65
|
1.28; 2.13
|
<0.001
|
1.47
|
1.13; 1.92
|
0.004
|
1.44
|
1.17; 1.78
|
0.001
|
1.20
|
0.97; 1.50
|
0.101
|
1.87
|
1.40; 2.49
|
<0.001
|
|
2
|
1.26
|
1.00; 1.60
|
0.054
|
1.49
|
1.11; 1.99
|
0.007
|
1.16
|
0.88; 1.53
|
0.308
|
1.24
|
0.99; 1.55
|
0.058
|
1.03
|
0.82; 1.29
|
0.801
|
1.33
|
0.95; 1.87
|
0.100
|
|
3
|
1.23
|
0.96; 1.59
|
0.103
|
1.34
|
0.96; 1.85
|
0.085
|
0.99
|
0.73; 1.34
|
0.991
|
1.21
|
0.96; 1.52
|
0.112
|
0.91
|
0.71; 1.16
|
0.440
|
1.03
|
0.72; 1.49
|
0.858
|
|
4
|
1.23
|
0.97; 1.55
|
0.094
|
1.47
|
1.11; 1.96
|
0.008
|
1.15
|
0.87; 1.52
|
0.321
|
1.18
|
0.93; 1.48
|
0.173
|
1.02
|
0.81; 1.28
|
0.890
|
1.23
|
0.87; 1.75
|
0.243
|
|
5
|
1.28
|
1.01; 1.63
|
0.043
|
1.48
|
1.11; 1.98
|
0.008
|
1.16
|
0.88; 1.54
|
0.284
|
1.24
|
1.00; 1.55
|
0.055
|
1.03
|
0.82; 1.29
|
0.799
|
1.32
|
0.94; 1.87
|
0.111
|
-
HR, hazard ratio for incident cardiovascular disease per 1 SD increase in lnMMP-1, -2, -3, -9 or -10 or lnTIMP-1, MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
-
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
-
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
-
Model 3 Model 2 + eGFR and Ln-UAE
-
Model 4 Model 2 + inflammatory z-score
-
Model 5 Model 2 + endothelial dysfunction z-score
